



This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently amended) A compound of the following formula (I):



wherein

P<sup>1</sup> and P<sup>2</sup> independently represent a polyethylene glycol (PEG) moiety;

Z<sup>1</sup> and Z<sup>2</sup> independently represent a polyclonal, monoclonal, multi-valent, multi-specific, humanized or chimeric antibody, a single chain antibody, a Fab fragment, a Fab' or F(ab')<sub>2</sub> fragment, or an epitope-binding fragment thereof;

X<sup>1</sup> and X<sup>2</sup> independently represent N;

A<sup>1</sup> and A<sup>2</sup> independently represent -NHCO-;

B<sup>1</sup> and B<sup>2</sup> independently represent -CO-;

V<sup>1</sup> and V<sup>2</sup> independently represent a covalent bond;

W<sup>1</sup> and W<sup>2</sup> independently represent -(CH<sub>2</sub>)<sub>w</sub>;

Y<sup>1</sup> and Y<sup>2</sup> independently represent -(CH<sub>2</sub>)<sub>y</sub>;

L<sup>1</sup> and L<sup>2</sup> independently represent a maleimide moiety residue, each of which is covalently linked to Z<sup>1</sup> and Z<sup>2</sup>, respectively, and each of which is covalently linked through the maleimide nitrogen atom to Y<sup>1</sup> and Y<sup>2</sup>, respectively;

M<sup>1</sup> represents -(CH<sub>2</sub>)<sub>m</sub>;

n-is-zero;



w is 1 or 2;

y is 1, 2, 3, 4, 5 or 6; and

m is 2.

2. (previously presented) A compound as claimed in claim 1 wherein  $Z^1$  and  $Z^2$  independently represent a whole antibody or a functionally active antibody fragment or derivative.

3. (currently amended) A compound of the following formula (III):



wherein

P<sup>1</sup> and P<sup>2</sup> independently represent a polyethylene glycol (PEG) moiety;

X<sup>1</sup> and X<sup>2</sup> independently represent  $\text{or N}$ ;

A<sup>1</sup> and A<sup>2</sup> independently represent  $\text{-NHCO-}$ ;

B<sup>1</sup> and B<sup>2</sup> independently represent  $\text{-CO-}$ ;

V<sup>1</sup> and V<sup>2</sup> independently represent a covalent bond;

W<sup>1</sup> and W<sup>2</sup> independently represent  $\text{-(CH}_2\text{)}_w$ ;

Y<sup>1</sup> and Y<sup>2</sup> independently represent  $\text{-(CH}_2\text{)}_y$ ;

M<sup>1</sup> represents  $\text{-(CH}_2\text{)}_m$ ;

~~n is zero;~~

w is 1 or 2;

y is 1, 2, 3, 4, 5 or 6; and

m is 2 .

4. (cancelled))

5. (cancelled)

6. (cancelled)

7. (cancelled)

8. (previously presented) A compound as claimed in claim 1 that is

DiFab'-conjugated 3-maleimidyl-N-(2-([3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino)-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

DiFab'-conjugated 3-maleimidyl-N-(2-([3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino)-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

9. (currently amended) A compound as claimed in claim [[4]] 3 that is

3-Maleimidyl-N-(2-([3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino)-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

3-Maleimidyl-N-(2-{{3-(maleimidyl)-propionyl}-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl]-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

10. (previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.

11. (new) A pharmaceutical composition comprising a compound as claimed in claim 2 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.

12. (new) A pharmaceutical composition comprising a compound as claimed in claim 8 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.